{"denoms":[{"counts":[{"groupId":"BG000","value":"157"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"311"}],"units":"Participants"}],"groups":[{"description":"Idelalisib (Zydelig®) 150 mg tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 6 total cycles) + rituximab (375 mg/m\\^2 on Day 1 and 500 mg/m\\^2 thereafter for at total of 6 infusions)","id":"BG000","title":"Idelalisib+Bendamustine+Rituximab"},{"description":"Placebo tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 6 total cycles) + rituximab intravenously (375 mg/m\\^2 on Day 1 and 500 mg/m\\^2 thereafter for at total of 6 infusions)","id":"BG001","title":"Placebo+Bendamustine+Rituximab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.7","value":"64"},{"groupId":"BG001","spread":"10.0","value":"63"},{"groupId":"BG002","spread":"9.4","value":"64"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"105"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"206"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"150"},{"groupId":"BG002","value":"302"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"Not Permitted"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"13"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"146"},{"groupId":"BG001","value":"149"},{"groupId":"BG002","value":"295"}]}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}]}],"title":"Not Permitted"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}]}],"title":"Romania"},{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"45"}]}],"title":"Hungary"},{"categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"60"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"20"}]}],"title":"United Kingdom"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"34"}]}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"19"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"27"}]}],"title":"Czech Republic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}],"title":"Belgium"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"33"}]}],"title":"Poland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]}],"title":"Italy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"34"}]}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"9"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"}]}],"title":"Croatia"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"58"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"124"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"57"}]}],"title":"Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"72"}]}],"title":"Stage IV"}],"description":"Rai staging is a way to categorize the disease progression of chronic lymphocytic leukemia (CLL) with higher stages reflecting increasing severity.\n\nRai Stage 0: Lymphocytosis only, Rai Stage I: Lymphocytosis with lymphadenopathy, Rai Stage II: Lymphocytosis with hepatomegaly or splenomegaly, Rai Stage III: Lymphocytosis with anemia, Rai Stage IV: Lymphocytosis with thrombocytopenia.","paramType":"COUNT_OF_PARTICIPANTS","title":"Rai Stage at Screening","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"108"}]}],"title":"Mutated"},{"categories":[{"measurements":[{"groupId":"BG000","value":"102"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"202"}]}],"title":"Unmutated"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Missing"}],"description":"The mutation status of the unique immunoglobulin gene (IgHV) rearrangement in the monoclonal proliferation of B-cells in CLL can be used to predict aggressiveness of the disease. Participants with a mutated IgHV gene usually have a less aggressive and more indolent disease, with longer overall survival. Participants with an unmutated IgHV gene usually have a more aggressive disease and shorter overall survival.","paramType":"COUNT_OF_PARTICIPANTS","title":"IgHV Mutation","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"146"},{"groupId":"BG001","value":"145"},{"groupId":"BG002","value":"291"}]}],"title":"Absent"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"19"}]}],"title":"Present"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Missing"}],"description":"Participants with CLL who have a 17p deletion lack a portion of the chromosome that acts to suppress cancer growth and is a recognized negative prognostic risk factor.","paramType":"COUNT_OF_PARTICIPANTS","title":"17p Deletion in CLL Cells","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-Treat (ITT) Analysis Set: who were randomized regardless of whether subjects received any study drug(s), or received a different regimen from the regimen to which they were randomized."}